Glycogen synthase kinase-3: An emerging therapeutic target for Alzheimers disease

Chinese Pharmacological Bulletin

Volumn 23, Issue 12, 2007, Pages

  Li, Ning ^a   Liu, Geng Tao ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Alzheimers disease; Glycogen synthase kinase 3; GSK3 inhibitors; Target drug

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3;

ALZHEIMER DISEASE; ARTICLE; CELL SURVIVAL; COMPLEX FORMATION; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME REGULATION; ENZYME SUBSTRATE; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

EID: 38349104351     PISSN: 10011978     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Grimes C A, Jope R S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling[J]. Prog Neurobiol,2001,65 (4):391-426.
2. Bhat R V, Shanley J, Correll M P, et al. Regulation and localization of tyrosine 216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration[J]. Proc Natl Acad Sci USA,2000,97(20):11074-9.
3. Patapoutian A, Reichardt L F. Roles of Wnt proteins in neural development and maintenance[J]. Curr Opin Neurobiol,2000,10 (3):392-9.
4. Watcharasit P, Bijur G N, Zmijewski J W, et al. Direct, activating interaction between glycogen synthase kinase-3 beta and p53 after DNA damage[J]. Proc Natl Acad Sci USA,2002,99(12):7951-5.
5. Watcharasit P, Bijur G N, Song L, et al. Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53[J]. J Biol Chem,2003,278(49):48872-9.
6. Diehl J A, Cheng M, Roussel M F, Sherr C J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization[J]. Genes Dev,1998,12(22):3499-511.
7. Bijur G N, Jope R S. Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3-kinase activation[J]. J Neurochem,2003, 87(6):1427-35.
8. Lucas F R, Goold R G, Gordon-Weeks P R, Salinas P C. Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium [J]. J Cell Sci,1998,111(Pt 10):1351-61.
9. Aubert J, Dunstan H, Chambers I, Smith A. Functional gene screening in embryonic stem cells implicates Wnt antagonism in neural differentiation[J]. Nat Biotechnol,2002,20(12):1240-5.
10. Morfini G, Szebenyi G, Elluru R, et al. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility[J]. EMBO J,2002,21(3):281-93.
11. Pap M, Cooper G M. Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3beta signaling pathway[J]. Mol Cell Biol, 2002,22(2):578-86.
12. Hoeflich K P, Luo J, Rubie E A, et al. Requirement for glycogen synthase kinase-3 beta in cell survival and NF-kappaB activation [J]. Nature,2000,06(6791):86-90.
13. Peng Y, Wang X L. Tau protein and Alzheimers disease[J]. Chin Pharmacol Bull,2004,20(6):601-5.
14. Hanger D P, Betts J C, Loviny T L, et al. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry[J]. J Neurochem,1998,71(6):2465-76.
15. Lucas J J, Hernandez F, Gomez-Ramos P, et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice[J]. EMBO J,2001,20(1 -2):27-39.
16. Spittaels K, Van den Haute C, Van Dorpe J, et al. Glycogen synthase kinase-3 beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice[J]. J Biol Chem,2000,275(52):41340-9.
17. Phiel C J, Wilson C A, Lee V M, Klein P S. GSK-3 alpha regulates production of Alzheimer's disease amyloid-beta peptides[J]. Nature,2003, 423(6938):435-9.
18. Cross D A, Culbert A A, Chalmers K A, et al. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death[J]. J Neurochem,2001,77(1):94-102.
19. Bhat R V, Leonov S, Luthman J, et al. Interactions between GSK3beta and caspase signalling pathways during NGF deprivation induced cell death[J]. J Alzheimers Dis,2002,4(4):291-301.
20. Grimes C A, Jope R S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium[J]. J Neurochem,2001, 78(6):1219-32.
21. Takashima A, Murayama M, Murayama O, et al. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau [J]. Proc Natl Acad Sci USA,1998,95(16):9637-41.
22. Gantier R, Gilbert D, Dumanchin C, et al. The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta[J]. Neurosci Lett,2000,283(3):217-20.
23. Nikoulina S E, Ciaraldi T P, Mudaliar S, et al. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes[J]. Diabetes,2000,49(2):263-71.
24. Jope R S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes[J]. Trends Pharmacol Sci,2003,24(9): 441-3.
25. Li L Y, Qin Z H, Liang Z Q. Neuroprotective actions and possible underlying molecular mechanisms of valproate[J]. Chin Pharmacol Bull,2007,23(3):295-8.